Clinical Trials Logo
  1. Home
  2. Other
  3. NCT06224621

Percutaneous Endocardial Septal Radiofrequency Ablation in Obstructive Hypertrophic Cardiomyopathy

Obstructive Hypertrophic Cardiomyopathy Clinical Trial

Official title:
Percutaneous Endocardial Septal Radiofrequency Ablation in the Treatment of Obstructive Hypertrophic Cardiomyopathy: a Prospective, Multicenter, Single-arm Objective Performance Criteria Trial

Clinical Trial Summary

This prospective, multicenter, single-arm objective performance criteria trial is designed to assess the efficacy and safety of the Percutaneous Endocardial Septal Radiofrequency Ablation (PESA) procedure in the treatment of obstructive hypertrophic cardiomyopathy (oHCM). The primary objectives include investigating: 1. the treatment efficacy and safety of PESA treatment in oHCM patients with either left ventricular outflow tract obstruction (LVOTO) or midventricular obstruction; 2. the impact of PESA treatment on the functional capacity, quality of life and long-term prognosis of oHCM patients with either LVOTO or midventricular obstruction.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT06224621
Study type Interventional
Source China National Center for Cardiovascular Diseases
Contact Lingmin Wu
Phone 18810488351
Email wlmxt2008@126.com
Status Recruiting
Phase N/A
Start date January 31, 2024
Completion date January 31, 2026
View Details
See also
  Status Clinical Trial Phase
Not yet recruiting NCT06023186 - Effect of Mavacamten Treatment on Coronary Flow Reserve in oHCM
Completed NCT05726799 - Use of Cryoenergy to Faciltate Myectomy in Hypertrophic Obstructive Cardiomyopathy: Comparison With the Classical Approach
Active, not recruiting NCT03723655 - A Long-Term Safety Extension Study of Mavacamten in Adults Who Have Completed MAVERICK-HCM or EXPLORER-HCM Phase 2/Phase 3
Completed NCT04603521 - Patients' Long-Term Survival of Obstructive Hypertrophic Cardiomyopathy (HCM)
Active, not recruiting NCT06211595 - Feasibility Study of the DragonFire for Hypertrophic Obstructive Cardiomyopathy N/A
Recruiting NCT06116968 - An Open-Label Study of Aficamten for Chinese Patients With Symptomatic oHCM Phase 3
Completed NCT03470545 - Clinical Study to Evaluate Mavacamten (MYK-461) in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy Phase 3
Recruiting NCT05879523 - A Trial of HRS-1893 in Healthy Volunteers and Patients With Obstructive Hypertrophic Cardiomyopathy Phase 1
Not yet recruiting NCT06146660 - A Study to Assess the Safety of Mavacamten in Korean Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy
Recruiting NCT05771987 - Permanent Pacing for Drug-refractory Symptomatic Patients With Obstructive Hypertrophic Cardiomyopathy. N/A
Active, not recruiting NCT05174416 - A Study to Evaluate the Efficacy and Safety of Mavacamten in Chinese Adults With Symptomatic Obstructive HCM Phase 3
Completed NCT01631006 - Effects of Continous Positive Airway Pressure (CPAP) in Hypertrophic Cardiomyopathy N/A
Not yet recruiting NCT06368037 - Feasibility Study of the DragonFire for Hypertrophic Obstructive Cardiomyopathy N/A
Recruiting NCT05489705 - A Prospective Registry Study to Assess Real-world Patient Characteristics, Treatment Patterns, and Longitudinal Outcomes in Patients Receiving Mavacamten and Other Treatments for Symptomatic Obstructive Hypertrophic Cardiomyopathy (Obstructive HCM)
Completed NCT06354556 - Effect of Verapamil Tablets on the Pharmacokinetic of HRS-1893 Tablets in Healthy Subjects Phase 1
Completed NCT04783766 - Safety, Tolerability and Pharmacokinetics Study of CK-3773274 Phase 1